Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy

Running, not enrolling

Conditions studied: Metastatic Non-small Cell Lung Cancer

In brief

The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \<1% metastatic non-small cell lung cancer (mNSCLC) treated with first-line (1L) nivolumab + ipilimumab + 2 cycles of chemotherapy (NIC) in the US

Key facts

Study ID

NCT07024862

Run by

Bristol-Myers Squibb

People needed

100

Starts

2024-10-24

Expected to finish

2025-06-30

Last updated by the study team

2025-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old at confirmed diagnosis with metastatic non-small cell lung cancer (NSCLC) (stage IV), squamous or non-squamous histology
• Initiated first-line (1L) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) regimen between 01 January 2018 and 2 years prior to study launch
• Tumor programmed death-ligand 1 (PD-L1) negative expression (i.e., PD-L1 <1%)
• No EGFR, ALK, or ROS1 genetic mutation (i.e., wild type)
• Minimum of 6 months of follow-up after initiation of 1L NIC*

You may not qualify if…

• Any prior systemic therapy for metastatic non-small cell lung cancer (NSCLC)

Where it is running

• Cardinal Health — Dublin, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.